Management of metastatic bone disease
Management of metastatic bone disease is a research topic within Surgery. Science Explorer counts 22k research works in it since 1950. 12.8% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the management of spinal metastatic tumors, including the use of radiotherapy and surgical strategies for palliative treatment. It explores prognostic factors, vertebral compression fractures, and the role of stereotactic radiosurgery in addressing metastatic epidural spinal cord compression. The cluster also discusses the challenges and advancements in managing bone metastases in the spine.
- Spinal Metastases
- Metastatic Spine Tumors
- Radiotherapy
- Surgical Management
- Palliative Treatment
- Prognostic Factors
- Vertebral Compression Fracture
- Stereotactic Radiosurgery
- Metastatic Epidural Spinal Cord Compression
- Bone Metastases
- Research works
- 22k fractional, since 1950
- In the world top 10%
- 2.8k per year above
- Top-10% rate
- 12.8% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +20% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Management of metastatic bone disease research?
By volume, the United States and China publish the most (1.1k and 596 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1.1k works
- 2 China 596 works
- 3 Japan 268 works
- 4 Germany 218 works
- 5 India 184 works
- 6 Italy 160 works
- 7 United Kingdom 158 works
- 8 Canada 134 works
- 9 France 102 works
- 10 South Korea 95 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Management of metastatic bone disease research?
By volume in 2022–2025, The University of Texas MD Anderson Cancer Center publishes the most Management of metastatic bone disease research, followed by Memorial Sloan Kettering Cancer Center and Neurological Surgery.
By volume, 2022–2025
- 1 The University of Texas MD Anderson Cancer CenterUnited States 39 works
- 2 Memorial Sloan Kettering Cancer CenterUnited States 35 works
- 3 Neurological SurgeryUnited States 22 works
- 4 Massachusetts General HospitalUnited States 21 works
- 5 Peking UniversityChina 18 works
- 6 Johns Hopkins UniversityUnited States 17 works
- 7 Harvard UniversityUnited States 16 works
- 8 University of TorontoCanada 15 works
- 9 Stanford UniversityUnited States 15 works
- 10 All India Institute of Medical SciencesIndia 14 works
Who are the leading researchers in Management of metastatic bone disease?
The most-cited researchers publishing on Management of metastatic bone disease include Fred Saad and Michael Weller.
- 1 Fred Saad Canada 2.7k citations
- 2 Michael Weller Switzerland 2.7k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Management of metastatic bone disease research done?
The largest centres of Management of metastatic bone disease research in 2022–2025 are Beijing (China), New York (United States), Tokyo (Japan) and Shanghai (China). Among places with at least 20 works in it, it is an unusually large share of all research in Rockville Centre and Heidelberg.
Largest cities, 2022–2025
Where it is the local speciality
- Rockville CentreUS · 22.2 works39×
- HeidelbergDE · 23.6 works5.8×
Location quotient: how much more of its research is in Management of metastatic bone disease than the world average.
Where is the best place to study Management of metastatic bone disease?
Among universities, judged by research, Harvard University, University of Toronto and Yale University score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Harvard UniversityUnited States | 47.7 | 20.2% | 3.2× | 16 | +70.8% |
| 2 | University of TorontoCanada | 41.6 | 19.1% | 2.7× | 15 | +45.1% |
| 3 | Yale UniversityUnited States | 39.6 | 28.1% | 2.2× | 9 | +56.1% |
| 4 | Johns Hopkins UniversityUnited States | 38.4 | 14.1% | 4.1× | 17 | +24.2% |
| 5 | Stanford UniversityUnited States | 36.0 | 16.5% | 3.1× | 14 | +30.9% |
| 6 | Heidelberg UniversityGermany | 35.0 | 18.5% | 4.2× | 9 | -13.5% |
| 7 | University of MiamiUnited States | 34.9 | 9.2% | 4.6× | 9 | +153.5% |
| 8 | Peking UniversityChina | 33.6 | 12.0% | 3.0× | 18 | +34.7% |
| 9 | Capital Medical UniversityChina | 28.6 | 11.7% | 4.3× | 10 | +61.3% |
| 10 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 28.5 | 14.7% | 2.9× | 11 | +43.4% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Management of metastatic bone disease research growing?
Output in 2018–2022 was 20% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Management of metastatic bone disease.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.